Hypereosinophilic syndrome - Recent developments in diagnosis and treatment;Hypereosinophiles syndrom: Aktueller stand der diagnostik und therapie

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 37, 2007, Pages 1892-1896

  Hellmich, B ^a,b,c   Holl Ulrich, K ^b   Gross, W L ^a,b  

^a Rheumaklinik Bad Bramstedt   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Medizinische Klinik

Author keywords

Eosinophilia; Hypereosinophilic syndrome; Imatinib; Interleukin 5

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYUREA; IMATINIB; MEPOLIZUMAB; METHOTREXATE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; EOSINOPHILIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; MYELOPROLIFERATIVE DISORDER; REVIEW; VASCULITIS; CLASSIFICATION; DRUG ANTAGONISM; HYPERSENSITIVITY; NEOPLASM; PARASITOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GLUCOCORTICOIDS; HUMANS; HYPEREOSINOPHILIC SYNDROME; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LUNG DISEASES; NEOPLASMS; PARASITIC DISEASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 34548783916     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984983     Document Type: Review

References (15)

1. Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994; 121: 648-653
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214
3. Di Stefano F, Amoroso A. Clinical approach to the patient with blood eosinophilia. Allerg Immunol (Paris) 2005; 37: 380-386
4. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97: 78-92
5. Gotlib J, Cools J, 3rd Malone JM, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891
6. Hellmich B, Metzler C, Gross W. Churg-Strauss Syndrom: aktueller Stand der Diagnostik und Therapie. Dtsch Med Wochenschr 2006; 131: 2270-2274
7. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, Wechsler ME, Weller PF The Hypereosinophilic Syndromes Working G. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117: 1292-1302
8. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-4666
9. Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg Strauss syndrome - successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22: S52-61
10. Parillo J, Fauci A, Wolff S. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978; 89: 167-172
11. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349: 2334-2339
12. Rothenberg ME, Gleich G, Roufosse F, Rosenwasser L, Weller PR. Steroid-sparing effects of anti-IL-5 monoclonal antibody (mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood 2006; 108: Abstract #373
13. Sade K, Mysels A, Levo Y, Kivity S. Eosinophilia: A study of 100 hospitalized patients. Eur J Intern Med 2007; 18: 196-201
14. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol 2007; 119: 1291-300
15. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341: 1112-1120